121 related articles for article (PubMed ID: 3303163)
1. Radiosensitization in vitro by cis-diammine (1,1-cyclobutanedicarboxylato) platinum(II) (carboplatin, JM8) and ethylenediammine-malonatoplatinum(II) (JM40).
Begg AC; van der Kolk PJ; Emondt J; Bartelink H
Radiother Oncol; 1987 Jun; 9(2):157-65. PubMed ID: 3303163
[TBL] [Abstract][Full Text] [Related]
2. Cell survival in four ovarian carcinoma xenografts following in vitro exposure to melphalan, cisplatin and cis-diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA,JM8).
Jones AC; Wilson PA; Steel GG
Cancer Chemother Pharmacol; 1984; 13(2):109-13. PubMed ID: 6380788
[TBL] [Abstract][Full Text] [Related]
3. Oral platinum analogue JM216, a radiosensitizer in oxic murine cells.
van de Vaart PJ; Klaren HM; Hofland I; Begg AC
Int J Radiat Biol; 1997 Dec; 72(6):675-83. PubMed ID: 9416790
[TBL] [Abstract][Full Text] [Related]
4. Hyperthermic enhancement of cell killing by five platinum complexes in human malignant melanoma cells grown as monolayer cultures and multicellular spheroids.
Kubota N; Kakehi M; Inada T
Int J Radiat Oncol Biol Phys; 1993 Feb; 25(3):491-7. PubMed ID: 8436528
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
Knox RJ; Friedlos F; Lydall DA; Roberts JJ
Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
[TBL] [Abstract][Full Text] [Related]
6. Resistance and cross-resistance of the IgM immunocytoma in the LOU/M Wsl rat for cisplatin, carboplatin, and iproplatin.
Steerenberg PA; Vendrik CP; de Jong WH; de Groot G; Fichtinger-Schepman AM; Scheefhals AP; Schornagel JH
Cancer Chemother Pharmacol; 1988; 22(1):51-7. PubMed ID: 3293840
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of radiation-induced cell kill by platinum complexes (carboplatin and iproplatin) in V79 cells.
O'Hara JA; Douple EB; Richmond RC
Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1419-22. PubMed ID: 3531116
[TBL] [Abstract][Full Text] [Related]
8. Platinum complexes as radiosensitizers of hypoxic mammalian cells.
Douple EB; Richmond RC
Br J Cancer Suppl; 1978 Jun; 3():98-102. PubMed ID: 277266
[TBL] [Abstract][Full Text] [Related]
9. Heat enhances the cytotoxicity of cis-diamminedichloroplatinum(II) and its analogues cis-1,1-cyclobutane-dicarboxylato(2R)-2-methyl-1,4- butanediammineplatinum(II) and cis-diammine(glycolato)platinum in vitro.
Takahashi I; Maehara Y; Kusumoto H; Kohnoe S; Sugimachi K
Cancer Chemother Pharmacol; 1993; 33(1):31-5. PubMed ID: 8269586
[TBL] [Abstract][Full Text] [Related]
10. [Platinum complexes as radiosensitizers in radiotherapy].
López Zúmel MC; Alvarez MV; Santos Peinado L
Rev Esp Oncol; 1984; 31(2):227-36. PubMed ID: 6100707
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of the cytotoxicity and DNA-damaging effects of cis-(diammino)(1,1-cyclobutanedicarboxylato)-platinum(II) and cis-diamminedichloroplatinum(II) on L1210 cells.
Micetich KC; Barnes D; Erickson LC
Cancer Res; 1985 Sep; 45(9):4043-7. PubMed ID: 3896476
[TBL] [Abstract][Full Text] [Related]
12. Preparation and characterization of platinum(II) and (IV) complexes of 1,3-diaminepropane and 1,4-diaminebutane: circumvention of cisplatin resistance and DNA interstrand cross-link formation in CH1cisR ovarian tumor cells.
Alvarez-Valdés A; Pérez JM; López-Solera I; Lannegrand R; Continente JM; Amo-Ochoa P; Camazón MJ; Solans X; Font-Bardía M; Navarro-Ranninger C
J Med Chem; 2002 Apr; 45(9):1835-44. PubMed ID: 11960495
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of mouse lip mucosa reactions after combinations of cis-diammine-1,1-cyclobutanedicarboxylate platinum (II) (CBDCA) and irradiation: single and fractionated treatments.
Landuyt W; Keizer J; Chin A; van der Schueren E
Int J Radiat Oncol Biol Phys; 1987 Sep; 13(9):1367-70. PubMed ID: 3305448
[TBL] [Abstract][Full Text] [Related]
14. The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP).
Ohmori T; Morikage T; Sugimoto Y; Fujiwara Y; Kasahara K; Nishio K; Ohta S; Sasaki Y; Takahashi T; Saijo N
Jpn J Cancer Res; 1993 Jan; 84(1):83-92. PubMed ID: 8383649
[TBL] [Abstract][Full Text] [Related]
15. Hypoxic cell sensitization to radiation damage by a new radiosensitizer: cis-dichloro-bis(1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole-N3)platinum(II) (flap).
Bales JR; Sadler PJ; Coulson CJ; Laverick M; Nias AH
Br J Cancer; 1982 Nov; 46(5):701-5. PubMed ID: 6890846
[TBL] [Abstract][Full Text] [Related]
16. Radiosensitization of EMT6 cells by four platinum complexes.
Teicher BA; Rockwell S; Lee JB
Int J Radiat Oncol Biol Phys; 1985 May; 11(5):937-41. PubMed ID: 4039304
[TBL] [Abstract][Full Text] [Related]
17. Blood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicarboxylate platinum (II) (CBDCA) in cancer patients.
Sharma H; Thatcher N; Baer J; Zaki A; Smith A; McAucliffe CA; Crowther D; Owens S; Fox BW
Cancer Chemother Pharmacol; 1983; 11(1):5-7. PubMed ID: 6349844
[TBL] [Abstract][Full Text] [Related]
18. Carboplatin as a potentiator of radiation therapy.
Douple EB; Richmond RC; O'Hara JA; Coughlin CT
Cancer Treat Rev; 1985 Sep; 12 Suppl A():111-24. PubMed ID: 3910216
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.
Harland SJ; Newell DR; Siddik ZH; Chadwick R; Calvert AH; Harrap KR
Cancer Res; 1984 Apr; 44(4):1693-7. PubMed ID: 6367971
[TBL] [Abstract][Full Text] [Related]
20. Diethyldithiocarbamate modulation of murine bone marrow toxicity induced by cis-diammine(cyclobutanedicarboxylato)platinum (II).
Schmalbach TK; Borch RF
Cancer Res; 1989 Dec; 49(23):6629-33. PubMed ID: 2555048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
